Is Starlink Set For The Largest IPO In History?

He turned PayPal from a tiny, off-the-radar startup… to a massive $64 billion giant. Then, he did it again with Tesla… which is up more than 19,500% since 2010. For perspective, that turns $100 invested into almost $20,000!

Jason Cole Biography and Net Worth

Insider of bluebird bio

Jason Cole has served as our chief operating & legal officer since February 2019 after serving as our chief legal officer for three years and our senior vice president, general counsel for two years. Prior to joining bluebird in 2014, Jason served as executive vice president, corporate development and general counsel at Zalicus Inc. from September 2011 through March 2014, and as senior vice president, general counsel of Zalicus, and its predecessor company CombinatoRx, Inc. from January 2006 to September 2011. From 1999 to 2006, Jason was a corporate and securities attorney at Ropes & Gray LLP. Mr. Cole holds an A.B. in government from Dartmouth College and a J.D. from Columbia University School of Law.

What is Jason Cole's net worth?: The estimated net worth of Jason Cole is at least $80,554.50 as of August 19th, 2022. Cole owns 9,477 shares of bluebird bio stock worth more than $80,555 as of December 21st. This net worth estimate does not reflect any other investments that Cole may own. Learn More about Jason Cole's net worth.
How do I contact Jason Cole?: The corporate mailing address for Cole and other bluebird bio executives is 60 BINNEY STREET, CAMBRIDGE MA, 02142. bluebird bio can also be reached via phone at (339) 499-9300 and via email at [email protected]. Learn More on Jason Cole's contact information.
Has Jason Cole been buying or selling shares of bluebird bio?: Jason Cole has not been actively trading shares of bluebird bio during the last quarter. Most recently, Jason Cole sold 709 shares of the business's stock in a transaction on Friday, August 19th. The shares were sold at an average price of $110.60, for a transaction totalling $78,415.40. Following the completion of the sale, the insider now directly owns 9,477 shares of the company's stock, valued at $1,048,156.20. Learn More on Jason Cole's trading history.
Who are bluebird bio's active insiders?: bluebird bio's insider roster includes Jason Cole (Insider), David Davidson (Insider), Nick Leschly (CEO), Andrew Obenshain (Insider), and Jessica Whitten (CAO). Learn More on bluebird bio's active insiders.
Are insiders buying or selling shares of bluebird bio?: During the last year, insiders at the biotechnology company sold shares 5 times. They sold a total of 463 shares worth more than $9,849.60. The most recent insider tranaction occured on December, 10th when CEO Andrew Obenshain sold 48 shares worth more than $403.20. Insiders at bluebird bio own 1.4% of the company. Learn More about insider trades at bluebird bio.
Information on this page was last updated on 12/10/2024.

Jason Cole Insider Trading History at bluebird bio

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
8/19/2022	Sell	709	$110.60	$78,415.40	9,477
8/4/2022	Sell	372	$87.80	$32,661.60	10,187
1/10/2022	Sell	79	$188.00	$14,852.00
2/25/2019	Sell	312	$3,004.80	$937,497.60	1,434
7/9/2018	Sell	256	$3,405.00	$871,680.00	1,084
1/30/2018	Sell	1,249	$3,918.20	$4,893,831.80	2,239
1/5/2018	Sell	56	$3,467.60	$194,185.60	997
6/7/2017	Sell	862	$2,004.40	$1,727,792.80	1,543
3/16/2017	Sell	246	$2,001.40	$492,344.40	849
2/15/2017	Sell	33	$1,604.40	$52,945.20	602
2/14/2017	Sell	188	$1,600.20	$300,837.60	635
1/5/2017	Sell	27	$1,342.00	$36,234.00	469
10/9/2015	Sell	249	$1,738.20	$432,811.80
9/9/2015	Sell	99	$2,731.20	$270,388.80
7/9/2015	Sell	249	$3,163.80	$787,786.20

Jason Cole Buying and Selling Activity at bluebird bio

bluebird bio Company Overview

bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy. The company's clinical development programs include HGB-205, HGB-206, and HGB-210 to evaluate the safety and efficacy of lovo-cel in the treatment of patients with SCD; and HGB-204, HGB-205, HGB-207, and HGB-212 to evaluate the safety and efficacy of beti-cel in the treatment of patients with ß-thalassemia. It has license agreement with Orchard Therapeutics Limited. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was incorporated in 1992 and is headquartered in Somerville, Massachusetts.

Today's Range

Now: $8.50

$7.94

$9.80

50 Day Range

MA: $8.53

$5.89

$14.73

2 Week Range

Now: $8.50

$5.80

$38.40

Volume

899,239 shs

Average Volume

398,183 shs

Market Capitalization

$82.64 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.72

Is Starlink Set For The Largest IPO In History?

From Paradigm Press | Ad

Click here now for the urgent details.